Replies to post #195621 on Innovation Pharmaceuticals Inc (IPIX)

[Astavakra]

I believe that they had the 400 cohort in mind from the start and therefor chose to use an adaptive design. After seeing safety at the highest dosage, they added the ten to that cohort. If the 400mg arm had caused bad AEs, for example, the patients would be in danger and the trial might have been jeopardized. So, they started with a smaller 400mg group and expanded. IMO